A Phase 1, First-in-human, Single-arm, Multi-center, Open-label, Repeated‑Dose, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0274 in Patients With Advanced HER2-positive Solid Tumors

Trial Profile

A Phase 1, First-in-human, Single-arm, Multi-center, Open-label, Repeated‑Dose, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0274 in Patients With Advanced HER2-positive Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs MP 0274 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Molecular Partners AG
  • Most Recent Events

    • 08 Feb 2018 According to Molecular Partners AG media release, the company expects initial safety data in Q4 2018, and the first efficacy data expected in 2019. Enrolment initiation in this trial was announced in Q4 2017.
    • 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top